Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226050 · ClinicalTrials.gov registry record · Phase 2
CLF065 for Chronic Pouchitis
A Phase 2 study of Pouchitis, sponsored by Calibr, a division of Scripps Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07226050 is a Phase 2 study of Pouchitis that is actively recruiting participants, run by Calibr, a division of Scripps Research. The registered enrollment target is 20 participants, below the 24-participant average among 5 other Pouchitis trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07226050, a Phase 2 study of Pouchitis, is actively recruiting participants, sponsored by Calibr, a division of Scripps Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is to evaluate investigational compound CLF065 as a treatment for adult patients with chronic pouchitis. The goals are to establish the safety, feasibility and efficacy of weekly dosing of long acting CLF065 versus placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CLF065
Study Locations (1)
California
- Phillip Fleshner, M.D. Inc - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-03-05 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226050
The ClinicalTrials.gov registry entry for NCT07226050 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 24-participant average among 5 other Pouchitis trials with a reported enrollment target (17% lower). The listed sponsor is Calibr, a division of Scripps Research, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pouchitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07226050 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07226050 about?
NCT07226050 is a clinical study titled "CLF065 for Chronic Pouchitis". This clinical trial is to evaluate investigational compound CLF065 as a treatment for adult patients with chronic pouchitis. The goals are to establish the safety, feasibility and efficacy of weekly dosing of long acting CLF065 versus placebo.
What is the current status of trial NCT07226050?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-03-05. Estimated completion is 2027-06.
What conditions does trial NCT07226050 study?
This clinical trial studies the following conditions: Pouchitis.
What interventions are being tested in trial NCT07226050?
The interventions under investigation include: Placebo (DRUG), CLF065 (DRUG).
Who is sponsoring clinical trial NCT07226050?
This trial is sponsored by Calibr, a division of Scripps Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226050 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pouchitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
RECRUITING · Phase 4
-
Fecal Microbiota Transplant for Patients With Chronic Pouchitis
RECRUITING · Early Phase 1
-
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
RECRUITING · Phase 4
-
Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis
COMPLETED · NA
-
Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.